ubs maintains buy rating for novartis with target of 111 francs

UBS has given Novartis a 'Buy' rating and set a price target of 111 francs based on insights from a recent conference.

CFO Harry Kirsch expressed optimism about the company's growth prospects for 2025, coinciding with the expiration of the Entresto patent.

Analyst Matthew Weston highlighted this confidence in a report released on Thursday. The endorsement from UBS suggests that Novartis is well-positioned to navigate challenges, particularly patent expirations. This information may be relevant to investors assessing growth potential in the pharmaceutical sector.

Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings